In addition, some evidence of benefit has been observed in breast cancer patients treated with Trastuzumab (anti-HER2) and in melanoma patients treated with Bevacizumab (anti-VEGF) [290,293]. This evidence concerns the gene VEGFA and breast carcinoma.